Role of Registries in Medicare Coverage of New Alzheimer Disease Drugs.

Odouard, Ilina C; Socal, Mariana P; Anderson, Gerard F

Odouard, Ilina C; Socal, Mariana P; Anderson, Gerard F.

Afiliación

Odouard IC; Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Socal MP; Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Anderson GF; Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

JAMA ; 330(14): 1331-1332, 2023 Oct 10.

Article en En | MEDLINE | ID: mdl-37755921

This Viewpoint discusses how the design of the Centers for Medicare & Medicaid Services (CMS) registry could impact Medicare's ability to evaluate whether monoclonal antibodies are reasonable and necessary for patients with Alzheimer disease and help physicians understand when the drug is most beneficial.

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: JAMA Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google